Saturday 17 October 2026
Export BIOA’s income statement to Excel — free account
BioAge Labs, Inc.
BIOA Healthcare Drug Manufacturers Specialty & Generic
BioAge Labs, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million. In the quarter to June 2026, revenue grew 1.62%, EPS grew 3.33%, free cash flow grew 2.68% and total debt fell 83.6%, each against the same quarter a year earlier.
4.82
0.53
−9.91%
Follow BIOA
BioAge Labs, Inc. (BIOA) P/E ratio
BioAge Labs, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 5.9× (June 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.4× | (18.97%) |
| 2 more quarters | Free account |
Against its own ten years
Low 0.0×
High 5.9×
Ten-year median
0.0×
Current reading's percentile
63
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| LFCR Lifecore Biomedical, Inc. compare | n/m |
| CGC Canopy Growth Corporation compare | n/m |
| AKBA Akebia Therapeutics, Inc. compare | n/m |
| TKNO Alpha Teknova, Inc. compare | n/m |
| SIGA Siga Technologies Inc. compare | n/m |
| ACB Aurora Cannabis Inc. compare | n/m |
| BIOA BioAge Labs, Inc. | n/m |
| EBS Emergent Biosolutions Inc. compare | n/m |
| ANIK Anika Therapeutics Inc. compare | n/m |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)